Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AGIO NASDAQ:RYTM NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$90.76+0.3%$84.74$4.77▼$98.64$7.04B0.391.02 million shs795,729 shsAGIOAgios Pharmaceuticals$43.33+2.9%$39.01$23.42▼$62.58$2.45B0.83542,600 shs342,945 shsRYTMRhythm Pharmaceuticals$110.47+1.2%$101.55$45.90▼$113.91$7.25B2.12541,885 shs356,081 shsVRNAVerona Pharma PLC American Depositary Share$106.91$106.41$31.09▼$106.93$9.21B0.051.46 million shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+0.32%-2.12%+9.95%+36.50%+782.88%AGIOAgios Pharmaceuticals+2.95%+2.36%+16.10%+8.33%-2.26%RYTMRhythm Pharmaceuticals+1.24%+0.17%+13.99%+27.78%+125.36%VRNAVerona Pharma PLC American Depositary Share0.00%0.00%+0.49%+1.53%+206.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$90.76+0.3%$84.74$4.77▼$98.64$7.04B0.391.02 million shs795,729 shsAGIOAgios Pharmaceuticals$43.33+2.9%$39.01$23.42▼$62.58$2.45B0.83542,600 shs342,945 shsRYTMRhythm Pharmaceuticals$110.47+1.2%$101.55$45.90▼$113.91$7.25B2.12541,885 shs356,081 shsVRNAVerona Pharma PLC American Depositary Share$106.91$106.41$31.09▼$106.93$9.21B0.051.46 million shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+0.32%-2.12%+9.95%+36.50%+782.88%AGIOAgios Pharmaceuticals+2.95%+2.36%+16.10%+8.33%-2.26%RYTMRhythm Pharmaceuticals+1.24%+0.17%+13.99%+27.78%+125.36%VRNAVerona Pharma PLC American Depositary Share0.00%0.00%+0.49%+1.53%+206.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.91Moderate Buy$114.2525.88% UpsideAGIOAgios Pharmaceuticals 2.57Moderate Buy$57.2532.13% UpsideRYTMRhythm Pharmaceuticals 2.94Moderate Buy$107.21-2.95% DownsideVRNAVerona Pharma PLC American Depositary Share 2.07Hold$109.001.95% UpsideCurrent Analyst Ratings BreakdownLatest AGIO, VRNA, RYTM, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ABVXAbivaxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025AGIOAgios PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/17/2025RYTMRhythm PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$157.00 ➝ $139.0010/16/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$122.00 ➝ $129.0010/13/2025ABVXAbivaxBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$142.0010/13/2025ABVXAbivaxBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$142.0010/10/2025ABVXAbivaxGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$101.00 ➝ $150.0010/8/2025ABVXAbivaxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AGIOAgios PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025RYTMRhythm PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VRNAVerona Pharma PLC American Depositary ShareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAGIOAgios Pharmaceuticals$36.50M68.97N/AN/A$27.02 per share1.60RYTMRhythm Pharmaceuticals$130.13M56.39N/AN/A$0.35 per share315.63VRNAVerona Pharma PLC American Depositary Share$42.28M217.94N/AN/A$2.56 per share41.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAGIOAgios Pharmaceuticals$673.72M$11.003.94N/AN/A1,590.42%-3.49%-3.23%10/30/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,563.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest AGIO, VRNA, RYTM, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025RYTMRhythm Pharmaceuticals-$0.72N/AN/AN/A$50.71 millionN/A11/3/2025Q3 2025VRNAVerona Pharma PLC American Depositary Share$0.17N/AN/AN/A$86.72 millionN/A10/30/2025Q3 2025AGIOAgios Pharmaceuticals-$1.94N/AN/AN/A$10.49 millionN/A9/8/2025Q2 2025ABVXAbivax-$0.90-$0.86+$0.04-$0.86$1.35 millionN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A0.770.77AGIOAgios PharmaceuticalsN/A14.4814.04RYTMRhythm PharmaceuticalsN/A2.792.64VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AGIOAgios PharmaceuticalsN/ARYTMRhythm PharmaceuticalsN/AVRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAGIOAgios Pharmaceuticals4.30%RYTMRhythm Pharmaceuticals6.10%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6177.83 millionN/ANot OptionableAGIOAgios Pharmaceuticals39058.10 million55.60 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableVRNAVerona Pharma PLC American Depositary Share3086.19 million82.06 millionOptionableAGIO, VRNA, RYTM, and ABVX HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Consensus Rating of "Hold" by BrokeragesOctober 13, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVerona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to SuspendOctober 8, 2025 | msn.comCantor Fitzgerald Reiterates "Overweight" Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)October 8, 2025 | marketbeat.comMatisse Capital Cuts Holdings in Verona Pharma PLC American Depositary Share $VRNAOctober 8, 2025 | marketbeat.com4,249 Shares in Verona Pharma PLC American Depositary Share $VRNA Acquired by Wealth Enhancement Advisory Services LLCOctober 8, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 52-Week High - Still a Buy?October 7, 2025 | marketbeat.comBingham Private Wealth LLC Takes $240,000 Position in Verona Pharma PLC American Depositary Share $VRNAOctober 7, 2025 | marketbeat.comPlatinum Investment Management Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNAOctober 2, 2025 | marketbeat.comAMI Asset Management Corp Sells 19,561 Shares of Verona Pharma PLC American Depositary Share $VRNAOctober 2, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High - Here's WhyOctober 1, 2025 | marketbeat.comVerona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD PortfolioSeptember 30, 2025 | insidermonkey.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 1-Year High - Should You Buy?September 25, 2025 | marketbeat.comHere’s What Lifted Verona Pharma (VRNA) in Q2September 25, 2025 | insidermonkey.comShareholders of Verona Pharma Approve Proposed Acquisition by MerckSeptember 24, 2025 | globenewswire.comVerona Pharma (VRNA) Rebounded from Challenging Q1September 16, 2025 | msn.comVerona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025September 16, 2025 | globenewswire.comHere’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%September 12, 2025 | insidermonkey.comHere’s How Wall Street is Reacting to Verona Pharma (VRNA)’s AcquisitionAugust 28, 2025 | finance.yahoo.comAll You Need to Know About Verona Pharma (VRNA) Rating Upgrade to BuyAugust 12, 2025 | zacks.comJames Aloysius Brady Sells 824 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockAugust 6, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGIO, VRNA, RYTM, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$90.76 +0.29 (+0.32%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$91.96 +1.21 (+1.33%) As of 10/24/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Agios Pharmaceuticals NASDAQ:AGIO$43.33 +1.24 (+2.95%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$43.34 +0.01 (+0.01%) As of 10/24/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Rhythm Pharmaceuticals NASDAQ:RYTM$110.47 +1.35 (+1.24%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$110.44 -0.03 (-0.03%) As of 10/24/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$106.91 0.00 (0.00%) As of 10/7/2025Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
